Role of the Epigenome in Heart Failure.
DNA modification
cardiac fibrosis
cardiac hypertrophy
epigenetics
gene regulation
histone modification
Journal
Physiological reviews
ISSN: 1522-1210
Titre abrégé: Physiol Rev
Pays: United States
ID NLM: 0231714
Informations de publication
Date de publication:
01 10 2020
01 10 2020
Historique:
pubmed:
25
4
2020
medline:
21
10
2020
entrez:
25
4
2020
Statut:
ppublish
Résumé
Gene expression is needed for the maintenance of heart function under normal conditions and in response to stress. Each cell type of the heart has a specific program controlling transcription. Different types of stress induce modifications of these programs and, if prolonged, can lead to altered cardiac phenotype and, eventually, to heart failure. The transcriptional status of a gene is regulated by the epigenome, a complex network of DNA and histone modifications. Until a few years ago, our understanding of the role of the epigenome in heart disease was limited to that played by histone deacetylation. But over the last decade, the consequences for the maintenance of homeostasis in the heart and for the development of cardiac hypertrophy of a number of other modifications, including DNA methylation and hydroxymethylation, histone methylation and acetylation, and changes in chromatin architecture, have become better understood. Indeed, it is now clear that many levels of regulation contribute to defining the epigenetic landscape required for correct cardiomyocyte function, and that their perturbation is responsible for cardiac hypertrophy and fibrosis. Here, we review these aspects and draw a picture of what epigenetic modification may imply at the therapeutic level for heart failure.
Identifiants
pubmed: 32326823
doi: 10.1152/physrev.00037.2019
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1753-1777Subventions
Organisme : European Research Council
ID : 294609
Pays : International